A searchable index of real negative results, null findings, and replication failures from the published literature — so you can learn what didn't work before repeating it.
WASTE indexes published research — it does not host or republish full papers. Each entry is a metadata record (title, authors, DOI) compiled from open scholarly databases, with the abstract shown in full only where the paper is openly licensed (e.g. Creative Commons); otherwise a short excerpt is shown for reference under fair use. WASTE classifies each work by failure type; classifications are automated and approximate.
21379 results · page 688 of 713
Haslam A, Olivier T, Prasad V · 2023 · ESMO open
Background The statistical plan of a phase II trial should balance minimizing the premature termination of potentially beneficial therapies (i.e. false negatives) and the further, costly testing of ineffective drugs (i.e. false positives).…
Nemcova Y, Knotek P, Jadrná I et al. · 2024 · Journal of phycology
Mallomonas thrive primarily in freshwaters and dominate plankton communities, especially in oligotrophic waters. The cells have a siliceous cell covering of regularly arranged scales. Despite their ecological importance, the intricate…
Wang J, Lan X, Chen P et al. · 2024 · Crop Protection
Unmanned Aerial Spraying Systems (UASS) have garnered substantial market attention as efficient tools for applying Plant Protection Products (PPPs). However, their application has primarily focused on low-growing crops such as rice and…
Lamouille-Hébert M, Arthaud F, Besnard A et al. · 2024 · Preprint
Abstract Climate change is one of the main drivers of species erosion. Rapidly changing climate in the form of warming, drying, and habitat isolation causes freshwater species to change their spatial extent, as most species have little…
Albuquerque-Silva MM, Oliveira MTd, de Oliveira AFM et al. · 2024 · Preprint
This study explored the correlation between concentrations of phenolic compounds (phenols, tannins, and flavonoids) and the versatility of woody medicinal plants in the Caatinga, a seasonally dry forest region in Brazil. We examined…
Cederholm C, Nilsson M, Oliva D · 2026 · Preprint
Abstract It is well established that patients undergoing chemotherapy for cancer experience reduced Quality of Life (QoL) across physical, cognitive, emotional, and social dimensions. The relationship between cancer and QoL is complex;…
Kramer MR, Bartolome S, Saggar R et al. · 2026 · Preprint
Abstract Background Combination therapy is recommended for pulmonary arterial hypertension (PAH), part of which generally includes prostanoids, which affect both the vascular tone and vessel remodeling seen in PAH. This study tested…
Pahwa R, Elble R, Hauser RA et al. · 2026 · Parkinsonism & related disorders
Introduction Effective treatments for essential tremor (ET) are needed. EveresT (NCT05122650) examined the efficacy and safety of suvecaltamide in patients with moderate to severe ET. Methods In this phase 2 b, 12-week, double-blind,…
Atthakitmongkol T, Chotiyaputta W, Lertwattanarak R et al. · 2026 · Journal of the Formosan Medical Association = Taiwan yi zhi
Background Tenofovir disoproxil fumarate (TDF) is an important drug to treat chronic hepatitis B (CHB) patients. However, long-term TDF therapy decreases renal function and bone mineral density (BMD). This study compared bone turnover…
Ozer BH, Lindhorst SM, Merrell RT et al. · 2026 · Preprint
Background GBM is one of the most common and most aggressive brain tumors in adults, and upfront standard of care treatment has limited efficacy. Immune checkpoint inhibitor strategies have significantly improved outcomes in various solid…
· 2026 · Cancer discovery
The NHS-Galleri trial, the first randomized, controlled trial of the multi-cancer early detection test Galleri, found that the test from GRAIL did not meet its primary endpoint, a reduction in late-stage cancers. Researchers say the result…
Burton JO, Izquierdo MJ, Linde C et al. · 2026 · Clinical kidney journal
Background and hypothesis Hyperkalaemia is common and potentially life-threatening in individuals with chronic kidney disease (CKD). While sodium zirconium cyclosilicate (SZC) is used in the hospital setting for hyperkalaemia management,…
Colombel JF, Garcia Olmo D, Chen ST et al. · 2026 · Gastroenterology
Background & aims The ADMIRE CD trial demonstrated the efficacy and safety of darvadstrocel in patients with complex perianal fistulas from Europe and Israel. The efficacy and safety of darvadstrocel in an expanded patient population was…
Mummery CJ, Mayorga AJ, Simmons A et al. · 2026 · Nature medicine
Triggering receptor expressed on myeloid cells 2 (TREM2) regulates microglial function and is implicated in Alzheimer's disease (AD) pathogenesis. Here we conducted a phase 2, randomized, double-blind, placebo-controlled trial of a…
Lu F, Lv C, Yang X et al. · 2025 · Lung cancer (Amsterdam, Netherlands)
Background EGFR tyrosine kinase inhibitors (EGFR-TKIs) have shown activity in the neoadjuvant setting of EGFR-mutant (EGFRm) non-small cell lung cancer; however, data on the combination of neoadjuvant EGFR-TKIs plus chemotherapy are…
Nikolcheva T, Pagano G, Anzures-Cabrera J et al. · 2026 · Lancet (London, England)
Background Prasinezumab has previously shown potential for reducing the progression of motor signs (Movement Disorder Society-sponsored Revision of the Unified Parkinson's Disease Rating Scale [MDS-UPDRS] Part III) in patients with…
Kjærsgaard L, Wiedemann J, Singer W et al. · 2026 · The Lancet. Neurology
Background Pathological aggregation and propagation of α-synuclein species drive disease progression in multiple system atrophy (MSA). We assessed the efficacy and safety of amlenetug, a monoclonal antibody targeting aggregated…
Wong BL, Phan HC, Péréon Y et al. · 2025 · Preprint
ABSTRACT Background In Duchenne muscular dystrophy (DMD), fibrosis is linked to connective tissue growth factor (CTGF) overexpression. Pamrevlumab, a fully human monoclonal antibody that inhibits CTGF activity, showed promise as a DMD…
Folkert IW, Mehran R, Sun R et al. · 2026 · Annals of surgical oncology
Background Hepatectomy for isolated colorectal liver metastases is associated with 5 year overall survival (OS) of 58% and is accepted as standard of care. However, the role of liver resection with unresectable low-volume lung metastases…
Connolly AM, Wong BL, Phan HC et al. · 2025 · Preprint
ABSTRACT Background In Duchenne muscular dystrophy (DMD), fibrosis is linked to connective tissue growth factor (CTGF) overexpression. Pamrevlumab, a fully human monoclonal antibody, inhibits CTGF activity and showed promise as a DMD…
Kircik L, Tsianakas A, Valenzuela F et al. · 2025 · The British journal of dermatology
Background Atopic dermatitis (AD), the most common inflammatory skin disorder, carries a significant public health burden. Many patients with moderate-to-severe AD are unable to achieve adequate disease control with topical treatment and…
Roupret M, Bertaut A, Pignot G et al. · 2026 · Annals of oncology : official journal of the European Society for Medical Oncology
Background Standard treatment of high-risk non-muscle-invasive bladder cancer (NMIBC) after transurethral resection of bladder tumor is intravesical instillation with Bacillus Calmette-Guérin (BCG) (induction and maintenance regimens);…
Falkenhorst J, Ivanyi P, Schulz T et al. · 2025 · Clinical cancer research : an official journal of the American Association for Cancer Research
Purpose Imatinib resistance is conferred by secondary mutations within the ATP-binding pocket or the activation loop of KIT in gastrointestinal stromal tumors (GIST). Ponatinib is active against KIT secondary activation loop and the…
Sahebjam S, Bazer DA, Rhun EL et al. · 2026 · Neuro-oncology advances
Background Abemaciclib is a selective cyclin-dependent kinase 4 and 6 inhibitor that penetrates the blood-brain barrier, resulting in comparable concentrations in tissue and plasma. The primary objective of this nonrandomized Simon…
Kim DW, Kim RD, Jimenez MM et al. · 2025 · The oncologist
Background Ramucirumab plus paclitaxel after progression on fluoropyrimidine/platinum in metastatic gastric (GA) and gastroesophageal junction adenocarcinoma (GEJC) has shown improvement in overall survival over paclitaxel alone. However,…
Leelahawong P, Ketsuwan C · 2026 · Journal of clinical medicine
Background/Objectives : To evaluate whether adjunctive silodosin improves the stone-free rate (SFR) and clinical outcomes of extracorporeal shock wave lithotripsy (ESWL) for renal calculi. Methods : In this prospective randomised…
Chibaudel B, Dourthe LM, André T et al. · 2026 · Signal transduction and targeted therapy
Managing unresectable metastatic colorectal cancer (mCRC) requires a comprehensive strategy. While chemotherapy, anti-angiogenic, and anti-epidermal growth factor receptor (EGFR) agents are available, strategy trials are needed to optimize…
Wheless MC, Stockton S, Soares HP et al. · 2025 · The oncologist
Background Mutations in TP53 are common in gastroesophageal cancer and portend a poor prognosis. Tumor cells with TP53 mutations increasingly rely on ataxia-telangiectasia and Rad3-related (ATR) protein to respond to and repair DNA damage…
Nagatani Y, Kiyota N, Yamazaki T et al. · 2026 · Japanese journal of clinical oncology
Background Salivary gland cancer (SGC) is rare and has various histological types. This rarity and heterogeneity have hindered elucidation of the therapeutic contribution of systemic therapy, including immune checkpoint inhibitors, to…
Linardou H, Papadopoulou K, Korfiatis N et al. · 2025 · European journal of cancer (Oxford, England : 1990)
Background Extensive stage small cell lung cancer (ES-SCLC) has poor prognosis, and first-line chemo-immunotherapy is now the standard-of-care. We hypothesized that intercalated immunotherapy administration in-between chemotherapy cycles,…